Available Technologies

ADDITIONAL FILTERS

Therapeutics

53 available technologies

Serotonin 2B Receptor Antagonism to Prevent Heart Valve Disease

Vanderbilt researchers have developed a novel approach that could potentially prevent or slow the progression of DAVD at its earliest possible stages so as to greatly increase patient quality of life. The initial mechanism which triggers fibrotic lesion formation occurs by phenotypic modulation of the aortic valve interstitial cells (AVICs) to the constitutive myofibroblast phenotype, producing significant amounts of extracellular matrix, similar to fibrotic remodeling in other tissues. Thus, desired goal to prevent DAVD is to control the phenotype modulation by specifically inhibiting molecular mechanisms that are known to cause activation of AVICs. This is achieved by inhibiting transforming growth factor-

A peptide therapeutic for atherosclerosis that restores lipid and cholesterol homeostasis

Atherosclerosis is a serious health concern; leading to 1.5 million heart attacks in the US each year and 795,000 strokes. Vanderbilt researchers have developed a peptide therapeutic that reduces development of atherosclerosis by 63% in mice fed a Western diet. This peptide's unique mechanism attacks the problem at the level of gene expression, returning lipid synthesis to homeostatic control, while also reducing cholesterol and triglyceride levels and improving liver function.

Assay for Dopamine Neuron Viability Using C. Elegans

The loss of DA neurons is a major feature of Parkinson's disease and other neuro-generative disorders. Vanderbilt researchers have established an in vivo screen for DA neuron protective agents and genes using the nematode C. elegans. Using green fluorescent protein (GFP) expression in C. elegans DA neurons, researchers have established that the nematode is sensitive to the mammalian neurotoxins that target DA neurons in mammalian models, consistent with an environmentally triggered loss of DA neurons. They also demonstrate that agents that block the nematode DA transporter or genetic ablation of the DA transporters protect these DA neurons. Thus, researchers have established lines and conditions that can allow for the facile screening, in a high throughput format, for agents or genes that may protect DA neurons from exogenous or endogenous neurotoxin-induced cell death. The system should also be useful for identifying novel pathway controlling presynaptic DA neuron function with potential applications to Schizophrenia, ADHD and addiction, where altered DA signaling has been proposed.

Novel Target Regulating Angiogenesis

Vanderbilt scientists have discovered that the receptor tyrosine phosphatase DEP-1 plays a significant role in angiogenesis and that modulation of the DEP-1 receptor with certain agents can affect endothelial cell growth. The research team has developed antibodies that bind to the ectodomain of a mammalian transmembrane protein known as DEP-1 (for density enhanced protein) or CD148. CD148 (also named DEP-1/PTPn) is a receptor-like protein tyrosine phosphatase that is abundantly expressed in vascular endothelial cells, hematopoietic-cell lineages, duct epithelia of thyroid, mammary and gastrointestinal tissues.

cSN50.1 peptide protects islets and stops type 1 diabetes

Researchers at Vanderbilt have developed a peptide therapeutic that rendered non-obese diabetic (NOD) mice diabetes-free and insulin-independent for at least one year after only 2 days of treatment at the early stage of disease.

Inhibition of Hyperacute Rejection in Pulmonary Xenograft

One of the several problems with organ transplantation is the actual procurement of needed organs. The number of patients requiring transplants far exceeds the number of available organs. Thus, tissues and organs from different species (xenografts) may offer help to many more potential organ donors, and consequently may help the organ shortage. However, many obstacles still remain with xenografts, with the major challenge being tissue/organ rejection. The need to reduce this rejection and the injury it can inflict upon the transplanted tissue/organ therefore remains high. Vanderbilt researchers have patented a technology that helps to prevent the rejection of transplanted tissues/organs and the injury that occurs to these tissues. This technology inhibits specific pathways that regulate platelet adhesion and aggregation, which have been linked to the rejection of transplanted tissues/organs.

Human Choline Transporter cDNA

Vanderbilt researchers report the isolation and characterization of a human cDNA encoding the high affinity, hemicholinium-3 sensitive choline transporter. This transporter is expressed in cholinergic terminals, and it provides for transport into cholinergic terminals of choline, the precursor for acetylcholine biosynthesis. The cDNA, through HC-3 radio ligand binding assays or choline transport assays, allows for high-throughput screening of choline transporter directed agents or as a negative screen to insure specificity for nicotinic and muscarinic acetylcholine receptor-directed agents (as well as other pharmaceutics). The choline transporter in vivo is highly regulated, and the human choline transporter's regulation is poorly understood. Use of the cDNA may allow for the development of novel cholinergic therapeutics targeted at choline transporter modulation. Antibodies directed against the human choline transporter should be useful probes of human cholinergic neurons. Sequences in the human choline transporter cDNA should allow for the generation of transporter specific gene probes that can be queried by in situ hybridization, PCR analyses of transporter gene expression or gene chip approaches evaluating alterations in presynaptic cholinergic function.

Novel PLD Inhibitors

Vanderbilt researchers have created the first isoform-selective phospholipase D (PLD) inhibitors. These highly potent inhibitors can significantly reduce PLD activity, creating a new class of anti-metastatic agents.

Peptide and Protein Fragmentation by Lysine Residue Originated Reactions

A method of modifying protein samples that comprises combining the sample with a peroxycarbonate solution and inserting the sample into a mass spectrometer. The present invention also includes methods of N-terminus characterization.

Human Monoclonal Antibodies to Infectious Diseases

Using human B cell hybridoma creation, and antibody engineering technologies, Dr. James E Crowe Jr.'s laboratory has developed an array of antibodies from full length human antibodies to Fab fragments and diabodies. Many of these antibodies are ready for a cooperate partner who can further develop these antibodies into biologic herapeutics. The table below is a sample of the antibodies they are currently researching and have available. In addition to these areas of research, Dr. Crowe is actively seeking collaborative opportunities to identify new interesting targets for future antibody engineering projects.

Multisubstrate Inhibitors of Histone Acetylation Increase the Cytotoxicity of Chemotherapeutic Agents

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.

A Novel Method for Importing Peptides with Functional Cargo Into the Cells

This technology enables the delivery of biological molecules into the interior of a cell. Such a delivery mechanism could be utilized in a variety of therapies including peptide, gene transfer and/or antisense therapy.

New NSAIDs derivatives for cancer treatment - Protective and less toxic, targeting PPAR gamma

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely-used anti-inflammatory and anti-pyretic therapeutic agents to treat human diseases. However, long-term use of NSAIDs comes with risks. Many NSAIDs are COX-1 inhibitors, which are associated with significant GI toxicities. The Marnett Lab at Vanderbilt University has developed new derivatives of NSAIDs that retain their protective effects but do not cause debilitating and potentially fatal toxicities.

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter